title: Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study.
abstract: BACKGROUND
  Quality of life assessments are important in the evaluation of new therapies for psoriasis.
  
  
  OBJECTIVE
  To determine the effect of voclosporin (VCS) treatment on quality of life in patients with psoriasis.
  
  
  METHODS
  451 plaque psoriasis patients with ≥  10% body surface area involvement were randomly assigned in a double-blind fashion to 1 of 4 treatment groups (placebo, VCS 0.2 mg kg(-1) BID, VCS 0.3 mg kg(-1) BID, and VCS 0.4 mg kg(-1) BID) for up to 12 weeks of treatment. Quality of life was assessed using the Dermatology Life Quality Index (DLQI) and the Psoriasis Disability Index (PDI).
  
  
  RESULTS
  At 12 weeks, patients treated with VCS 0.4 mg kg(-1) BID had statistically significantly more favourable assessments than placebo-treated patients in all domains of the DLQI and the PDI. Patients treated with VCS 0.3 mg kg(-1) BID had statistically significant improvements in 5 of 10 domains of the DLQI and all domains of the PDI. Patients treated with VCS 0.2 mg kg(-1) BID had statistically significant improvements in 4 of 10 domains of the DLQI and 2 of 4 domains of the PDI.
  
  
  CONCLUSIONS
  Treatment with VCS 0.4 mg kg(-1) BID significantly improves the quality of life of patients with psoriasis.
authors.affiliation: Ultranova Skincare, Barrie, ON, L4M-6L2 Canada. derm@ultranovatrials.ca
authors.forename: Rod
authors.initials: R
authors.lastname: Kunynetz
authors.forename: Wayne
authors.initials: W
authors.lastname: Carey
authors.forename: Richard
authors.initials: R
authors.lastname: Thomas
authors.forename: Darryl
authors.initials: D
authors.lastname: Toth
authors.forename: Ted
authors.initials: T
authors.lastname: Trafford
authors.forename: Ronald
authors.initials: R
authors.lastname: Vender
mesh_terms: D000328:Adult; D002170:Canada; D016572:Cyclosporine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; C484071:voclosporin; D016572:Cyclosporine